ABT-414

AbbVie Receives U.S. FDA Rare Pediatric Disease Designation for Investigational ABT-414 for the Treatment of a Type of Pediatric Brain Tumor known as Diffuse Intrinsic Pontine Glioma (DIPG)
AbbVie Receives U.S. FDA Rare Pediatric Disease Designation for Investigational ABT-414 for the Treatment of a Type of Pediatric Brain Tumor known as Diffuse Intrinsic Pontine Glioma (DIPG)
Yahoo
AbbVie
pediatric
brain tumors
Diffuse Intrinsic Pontine Glioma
ABT-414
Flag link:
AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meeting
AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meeting
Yahoo
AbbVie
glioblastoma
brain cancer
ASCO 2016
ABT-414
Flag link:
Most Popular News Headlines For Thursday, August 14 2014
Most Popular News Headlines For Thursday, August 14 2014
CP Wire
FDA
Kyprolis
Amgen
asthma
AstraZeneca
AbbVie
orphan drugs
ABT-414
female se
Flag link:
Most popular news headlines for Thursday, August 14 2014
FDA
Kyprolis
Amgen
asthma
AstraZeneca
AbbVie
orphan drugs
ABT-414
female se
Flag link:
AbbVie makes inroads in orphan drugs
AbbVie makes inroads in orphan drugs
Medical Marketing and Media
AbbVie
orphan drugs
glioblastoma multiforme
ABT-414
Flag link:
AbbVie heralds early success with its brain cancer-fighting armed antibody
AbbVie heralds early success with its brain cancer-fighting armed antibody
Fierce Biotech
glioblastoma multiforme
ABT-414
AbbVie
Flag link: